摘要
目的分析奥沙利铂联合表柔比星在中晚期原发性肝癌介入治疗中的疗效。方法该次研究时间为2016年1月-2017年8月,患者共为120例,将其随机分为观察组和对照组,两组患者均利用介入治疗,对照组患者采用奥沙利铂治疗,而观察组则采用奥沙利铂联合表柔比星。结果观察组患者的缓解率91.67%明显高于对照组73.33%(χ^2=6.984 1,P<0.05)。同时在不良反应发生率方面,观察组的为18.33%明显低于对照组35.00%(χ^2=4.241 4,P<0.05)。结论对于原发性肝癌介入治疗的患者,选择奥沙利铂联合表柔比星的治疗效果较为理想,可以延长患者的生存时间,保证患者的健康,同时不良反应较低,安全性较高,具有非常重要的临床意义。
Objective To analyze the efficacy of oxaliplatin combined with epirubicin in the interventional treatment of advanced primary liver cancer.Methods The study time was from January 2016 to August 2017.A total of 120 patients were randomly divided into observation group and control group.Both groups were treated with interventional therapy.The control group was treated with oxaliplatin treatment,while the observation group used oxaliplatin combined with epirubicin.Results The remission rate of the observation group was 91.67%,which was significantly higher than that of the control group 73.33%(χ^2=6.984 1,P<0.05).At the same time,in the incidence of adverse reactions,18.33% of the observation group was significantly lower than the control group 35.00%(χ^2=4.241 4,P<0.05).Conclusion For patients with primary liver cancer interventional therapy,the choice of oxaliplatin combined with epirubicin is ideal,which can prolong the survival time of patients and ensure the health of patients,with low adverse reactions and high safety,has very important clinical significance.
作者
杜更全
王海红
DU Geng-quan;WANG Hai-hong(Department of Oncology, Yanggu County People's Hospital, Yanggu, Shandong Province, 252300 China)
出处
《系统医学》
2019年第14期121-123,共3页
Systems Medicine
关键词
奥沙利铂
表柔比星
联合治疗
中晚期原发性肝癌
介入治疗
效果
Oxaliplatin
Epirubicin
Combination therapy
Advanced primary liver cancer
Interventional therapy
Effect
